The relationship among proton pump inhibitors, bone disease and fracture

Bibliography

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785-95
   Google Scholar
• Leslie WD, Lix LM, Langsetmo L, Construction of a FRAX((R)) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011;10:817-27
   Web of Science ®Google Scholar
• Berger C, Goltzman D, Langsetmo L, Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010;25:1948-57
   PubMed Web of Science ®Google Scholar
• Sawka AM, Thabane L, Papaioannou A, Health-related quality of life measurements in elderly canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2005;16:1836-40
   PubMed Web of Science ®Google Scholar
• Hallberg I, Rosenqvist AM, Kartous L, Health-related quality of life after osteoporotic fractures. Osteoporos Int 2004;15:834-41
   PubMed Web of Science ®Google Scholar
• Ioannidis G, Papaioannou A, Hopman WM, Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009;181:265-71
   PubMed Web of Science ®Google Scholar
• Hannan EL, Magaziner J, Wang JJ, Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:2736-42
   PubMed Web of Science ®Google Scholar
• Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996;156:1521-5
   PubMed Web of Science ®Google Scholar
• Morin S, Lix LM, Azimaee M, Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int 2010
   Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383-9
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000
   PubMed Web of Science ®Google Scholar
• Kanis J, Johnell O, Gullberg B, Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int 1999;9:45-54
   PubMed Web of Science ®Google Scholar
• Jette N, Lix LM, Metge CJ, Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011;68:107-12
   PubMed Web of Science ®Google Scholar
• Haney EM, Chan BK, Diem SJ, Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167:1246-51
   PubMed Web of Science ®Google Scholar
• Bolton JM, Metge C, Lix L, Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008;28:384-91
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bolton JM, Metge CJ, Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82
   PubMed Web of Science ®Google Scholar
• Grisso JA, Kelsey JL, Strom BL, Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med 1991;324:1326-31
   PubMed Web of Science ®Google Scholar
• Cumming RG, Klineberg RJ. Fall frequency and characteristics and the risk of hip fractures. J Am Geriatr Soc 1994;42:774-8
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Johnell O, Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-42
   PubMed Web of Science ®Google Scholar
• Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842-60
   PubMed Web of Science ®Google Scholar
• Sharma BK, Walt RP, Pounder RE, Optimal dose of oral omeprazole for maximal 24 h decrease of intragastric acidity. Gut 1984;25:957-64
   PubMed Web of Science ®Google Scholar
• Richter JE, Peura D, Benjamin SB, Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160:1810-16
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-413, 1413 e1-5
   PubMed Web of Science ®Google Scholar
• Ruigomez A, Garcia Rodriguez LA, Wallander MA, Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol 2006;101:2685-92
   PubMed Web of Science ®Google Scholar
• Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009;361:2548-56
   PubMed Web of Science ®Google Scholar
• Nguyen DM, El-Serag HB, Henderson L, Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299-304
   PubMed Web of Science ®Google Scholar
• Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44
   PubMed Web of Science ®Google Scholar
• Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010;170:747-8
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60
   PubMed Web of Science ®Google Scholar
• Gulmez SE, Holm A, Frederiksen H, Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5
   PubMed Web of Science ®Google Scholar
• Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-77
   PubMed Web of Science ®Google Scholar
• Regolisti G, Cabassi A, Parenti E, Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010;56:168-74
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ, Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-26
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008;28:951-9
   PubMed Web of Science ®Google Scholar
• de Vries F, Cooper AL, Cockle SM, Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009;20:1989-98
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010;139:93-101
   PubMed Web of Science ®Google Scholar
• Pouwels S, Lalmohamed A, Souverein P, Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2011;22:903-10
   PubMed Web of Science ®Google Scholar
• Roux C, Briot K, Gossec L, Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84:13-9
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE, Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251-9
   PubMed Web of Science ®Google Scholar
• Gray SL, LaCroix AZ, Larson J, Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010;170:765-71
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31:810-23
   PubMed Web of Science ®Google Scholar
• Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-3
   PubMed Web of Science ®Google Scholar
• Bo-Linn GW, Davis GR, Buddrus DJ, An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73:640-7
   PubMed Web of Science ®Google Scholar
• O'Connell MB, Madden DM, Murray AM, Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118:778-81
   PubMed Web of Science ®Google Scholar
• Graziani G, Badalamenti S, Como G, Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002;91:474-9
   PubMed Web of Science ®Google Scholar
• Hardy P, Sechet A, Hottelart C, Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998;22:569-73
   PubMed Web of Science ®Google Scholar
• Hansen KE, Jones AN, Lindstrom MJ, Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010;25:2510-19
   Web of Science ®Google Scholar
• Wright MJ, Sullivan RR, Gaffney-Stomberg E, Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010;25:2205-11
   PubMed Web of Science ®Google Scholar
• Abugassa S, Nordenstrom J, Eriksson S, Sjoden G. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 1993;76:1617-21
   PubMed Web of Science ®Google Scholar
• Chan FK, Tiu SC, Choi KL, Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 2003;88:3155-9
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010;138:896-904
   PubMed Web of Science ®Google Scholar
• Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys 2008;476:33-42
   PubMed Web of Science ®Google Scholar
• Tuukkanen J, Vaananen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986;38:123-5
   PubMed Web of Science ®Google Scholar
• Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21-5
   PubMed Web of Science ®Google Scholar
• Kocher MS, Kasser JR. Osteopetrosis. Am J Orthop 2003;32:222-8
   PubMedGoogle Scholar
• Lenart BA, Neviaser AS, Lyman S, Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-62
   PubMed Web of Science ®Google Scholar
• Ing-Lorenzini K, Desmeules J, Plachta O, Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a swiss university hospital. Drug Saf 2009;32:775-85
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Mamdani MM, Juurlink DN, Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; In press
   Google Scholar
• Roux C, Goldstein JL, Zhou X, Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int 2011; In press
   Google Scholar
• Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009;29:1219-29
   PubMed Web of Science ®Google Scholar
• Glew CM, Rentler RJ. Use of proton pump inhibitors and other acid suppressive medications in newly admitted nursing facility patients. J Am Med Dir Assoc 2007;8:607-9
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Jamal R, Murata GH, Step-down management of gastroesophageal reflux disease. Gastroenterology 2001;121:1095-100
   PubMed Web of Science ®Google Scholar
• Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940-4
   PubMed Web of Science ®Google Scholar
• Reimer C, Bytzer P. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol 2010;22:1182-8
   PubMed Web of Science ®Google Scholar